FDA Approves First-Line Pembrolizumab for Head/Neck Squamous Cell Carcinoma

Leggi l'articolo originale


The FDA approved pembrolizumab for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma

Lascia un commento